Formulary

Student Pharmacists Complete New AMCP Foundation/Pfizer, Inc. Oncology Summer Internship Program

Friday, November 20, 2020 - 11:59pm

ALEXANDRIA, Va., Nov. 20,2020 /PRNewswire/ --AMCP Foundation proudly recognizes two student pharmacists who recently completed the Managed Care: Oncology Summer Internship program with the generous support of Pfizer, Inc.'s US Oncology Organized Customer Team.

Key Points: 
  • ALEXANDRIA, Va., Nov. 20,2020 /PRNewswire/ --AMCP Foundation proudly recognizes two student pharmacists who recently completed the Managed Care: Oncology Summer Internship program with the generous support of Pfizer, Inc.'s US Oncology Organized Customer Team.
  • This internship launched in 2020, allowing trainees to work alongside industry experts to learn about formulary management, benefit design, and adherence with a focus on oncology.
  • Future leaders gained first-hand experience working in specialty pharmacy, oncology, and related business areas within pharmacy benefit management companies.
  • Following their remote placements, interns presented posters showcasing real-world data at AMCP 2020 Nexus Virtual on Wednesday, Oct. 21 ( view all Nexus 2020 Virtual posters ).

All Omada Health Chronic Care Programs Available on Evernorth Digital Health Formulary

Thursday, November 12, 2020 - 5:00pm

SAN FRANCISCO, Nov. 12, 2020 /PRNewswire-PRWeb/ --With the company's program for at-home physical therapy and personalized treatment for chronic pain joining programs for diabetes prevention, type 2 diabetes, and hypertension, Omada health now offers the widest range of digital health solutions on the Evernorth Digital Health Formulary.

Key Points: 
  • SAN FRANCISCO, Nov. 12, 2020 /PRNewswire-PRWeb/ --With the company's program for at-home physical therapy and personalized treatment for chronic pain joining programs for diabetes prevention, type 2 diabetes, and hypertension, Omada health now offers the widest range of digital health solutions on the Evernorth Digital Health Formulary.
  • Omada's programs for prevention, diabetes, and hypertension are currently available on the digital health formulary; the MSK program will be available beginning in 2021.
  • We're excited to partner with Evernorth, and to offer the most comprehensive set of solutions as their innovative digital health formulary leads an evolution of care delivery for digital health."
  • Omada Health is a digital care provider that empowers people to achieve their health goals through sustainable behavioral change.

Bioventus to Provide CVS Caremark® with its Portfolio of Preferred Options for Knee Osteoarthritis Patients Seeking Pain Relief

Tuesday, November 10, 2020 - 3:00pm

All three products will be among the four preferred standard formulary options of knee OA treatments for CVS Caremark members.

Key Points: 
  • All three products will be among the four preferred standard formulary options of knee OA treatments for CVS Caremark members.
  • CVS Caremark members now have access to the broadest HA portfolio available to patients and physicians in the US, said John Nosenzo, Chief Commercial Officer, Bioventus.
  • DUROLANE, GELSYN-3 and SUPARTZ FX, all from Bioventus, provide long lasting OA knee pain relief allowing patients to resume more active lives.
  • Risks can include general knee pain, warmth and redness or pain at the injection site.

The Confidio RED™ (Recommended Excluded Drug) List by Confidio is Now Enhanced

Tuesday, November 3, 2020 - 5:18pm

TOWSON, Md., Nov. 3, 2020 /PRNewswire/ --Confidio, atechnology-enabled pharmacy benefits consulting firm has completed its annual update of the Confidio REDList.

Key Points: 
  • TOWSON, Md., Nov. 3, 2020 /PRNewswire/ --Confidio, atechnology-enabled pharmacy benefits consulting firm has completed its annual update of the Confidio REDList.
  • "Confidio is committed to identifying opportunities for our clients to save additional dollars above and beyond what their current PBM does today.
  • The clinical team reviewed additional drugs during 2020, to enhance the Confidio RED list to maximize potential savings further.
  • Key features of the Confidio REDList include:
    Plan sponsors can strategically leverage the Confidio REDList with any PBM formulary design, utilization management programs and exclusions list.

Evernorth selects musculoskeletal care leader, Hinge Health for Digital Health Formulary

Thursday, October 15, 2020 - 1:00pm

SAN FRANCISCO, Oct. 15, 2020 /PRNewswire-PRWeb/ --Last week, Evernorth the health services segment of Cigna Corporation and parent company to Express Scripts, expanded its industry-first Digital Health Formulary to include Hinge Health, a comprehensive Digital MSK Clinic for back and joint care.

Key Points: 
  • SAN FRANCISCO, Oct. 15, 2020 /PRNewswire-PRWeb/ --Last week, Evernorth the health services segment of Cigna Corporation and parent company to Express Scripts, expanded its industry-first Digital Health Formulary to include Hinge Health, a comprehensive Digital MSK Clinic for back and joint care.
  • Hinge Health has 10x more customers than any other digital MSK solution, the most rigorous clinical/financial outcomes data, and most advanced enterprise readiness.
  • "Millions of Americans now have access to the most comprehensive Digital MSK Clinic through Hinge Health's partnership with Evernorth, a leader in innovation," said Hinge Health CEO and co-founder Daniel Perez.
  • "Evernorth led a rigorous evaluation to select Hinge Health to bring members complete care for back and joint pain at every stage of their journey from prevention to post-surgery care."

Omada MSK by Physera Selected for Evernorth's Digital Health Formulary

Wednesday, October 7, 2020 - 2:00pm

Omada MSK by Physera joins Omada's existing formulary programs for diabetes prevention, type 2 diabetes, and hypertension.

Key Points: 
  • Omada MSK by Physera joins Omada's existing formulary programs for diabetes prevention, type 2 diabetes, and hypertension.
  • Created in 2019, the Digital Health Formulary features solutions that are evaluated and measured on clinical effectiveness, usability, scalability, and interoperability.
  • "Evernorth has made rigorous evaluation a prerequisite for any solution included on its digital health formulary," said Omada CEO and Co-Founder Sean Duffy.
  • To date, health plans covering more than 20 million Americans offer solutions from Evernorth's Digital Health Formulary to their members.

Evernorth Continues Work to Reduce Costs and Improve Health With Expanded and Innovative Digital Health Formulary Platform

Wednesday, October 7, 2020 - 1:10pm

Created in 2019, the Digital Health Formulary features solutions that are evaluated and measured by physicians, pharmacists, and health research scientistsfor clinical effectiveness.

Key Points: 
  • Created in 2019, the Digital Health Formulary features solutions that are evaluated and measured by physicians, pharmacists, and health research scientistsfor clinical effectiveness.
  • In 2021, the Digital Health Formulary will add the following innovations to its industry-leading platform:
    Women's health: Wildflower Health - provides support for family planning, infertility, pregnancy, and post-partum.
  • To date, health plans covering more than 20 million Americans offer solutions from the Digital Health Formulary to their members.
  • For more information about the Evernorth Digital Health Formulary, please visit https://my.express-scripts.com/digital-health-formulary.html
    Evernorth is a new brand for Cigna's growing, high-performing health services portfolio.

AcelRx Announces DSUVIA® Added to the U.S. Department of Defense's Joint Deployment Formulary

Monday, September 14, 2020 - 1:30pm

The JDF is a core list of pharmaceutical products that are designated for deploying military units across all service branches.

Key Points: 
  • The JDF is a core list of pharmaceutical products that are designated for deploying military units across all service branches.
  • "DSUVIA's addition to the Joint Deployment Formulary continues to validate its importance as a key option in the treatment of acute pain and represents yet another significant milestone for AcelRx," said Vince Angotti, Chief Executive Officer at AcelRx Pharmaceuticals.
  • DSUVIA was designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with intravenous (IV) administration.
  • DSUVIA is a single-strength solid dosage form administered sublingually via a single-dose applicator (SDA) by healthcare professionals.

Agadia Launches New Healthcare Technology Solution to Shift the Paradigm of Formulary Benefit Management.

Wednesday, July 15, 2020 - 3:00pm

Custom integrations, real time updates, and ensured CMS Medicare compliance make this solution a top competitor in the space.

Key Points: 
  • Custom integrations, real time updates, and ensured CMS Medicare compliance make this solution a top competitor in the space.
  • FormularyHub enables health plans and pharmacy benefit managers to administer and manage formularies and provide actionable Formulary information to prescribers."
  • FormularyHub is a web-based solution allowing Health Plans & PBMs to control the creation, implementation and maintenance of custom and standard formularies.
  • Agadia is a leading healthcare technology company addressing the evolving needs of the managed care market with a suite of utilization management solutions in electronic prior authorization, MTM, Part D star ratings and adherence, and formulary benefit design.

Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Federal/Provincial/Territorial Public Drug Plan Formularies

Thursday, July 9, 2020 - 1:30pm

MONTREAL, July 09, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion on the Alberta Drug Benefit List (ADBL), the Saskatchewan Drug Plan, the Newfoundland and Labrador Prescription Drug Program (NLPDP) and the Yukon Drug Formulary for the treatment of Juvenile Idiopathic Arthritis (JIA).

Key Points: 
  • MONTREAL, July 09, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion on the Alberta Drug Benefit List (ADBL), the Saskatchewan Drug Plan, the Newfoundland and Labrador Prescription Drug Program (NLPDP) and the Yukon Drug Formulary for the treatment of Juvenile Idiopathic Arthritis (JIA).
  • TH has also been approved for inclusion on the Ontario Drug Benefit Formulary/Comparative Drug Index (ODB Formulary/CDI) and the Non-Insured Health Benefits Drug Benefit List for its full Health Canada-approved indication which includes approved use in both adults and adolescents.
  • TH is the longest acting corticosteroid for intra-articular injection, often lasting twice as long as comparator products.
  • Ken dEntremont, Chief Executive Officer of Medexus, commented, The inclusion of our TH on these public drug plan formularies in Canada enhances the accessibility of this therapy for pediatric and adult patients suffering from chronic inflammatory diseases including JIA and RA.